Literature DB >> 28482692

Heart rate and the risk of adverse outcomes in patients with heart failure with preserved ejection fraction.

Wesley T O'Neal1, Pratik B Sandesara1, Ayman Samman-Tahhan1, Heval M Kelli1, Muhammad Hammadah1, Elsayed Z Soliman2,3.   

Abstract

Background Although high resting heart rates are associated with adverse outcomes in heart failure with reduced ejection, the reports for heart failure with preserved ejection fraction (HFpEF) are conflicting. Design A secondary analysis was conducted in order to examine the relationship between resting heart rate and adverse outcomes in 2705 patients (mean age = 68 ± 10 years; 47% men; 88% white) with HFpEF who were in sinus rhythm from the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist Trial (TOPCAT). Methods Baseline heart rate was obtained from baseline electrocardiogram data. Outcomes were adjudicated by a clinical end-point committee and included the following factors: hospitalisation, hospitalisation for heart failure, death and cardiovascular death. Results Over a median follow-up of 3.4 years (25th-75th percentiles = 2.0-4.9 years), a total of 1157 hospitalisations, 311 hospitalizations for heart failure, 369 deaths and 233 cardiovascular deaths occurred. An increased risk (per 5-beats per minute [bpm] increase) for hospitalisation (hazard ratio [HR] = 1.03, 95% confidence interval [CI] = 1.004-1.060), hospitalisation for heart failure (HR = 1.10, 95% CI = 1.05-1.15), death (HR = 1.10, 95% CI = 1.06-1.16) and cardiovascular death (HR = 1.13, 95% CI = 1.07-1.19) was observed. When the analysis was limited to those who did not report the use of β-blockers, the magnitude of the association for each outcome (per 5-bpm increase) was not materially altered (hospitalisation: HR = 1.03, 95% CI = 0.97-1.09; hospitalisation for heart failure: HR = 1.12, 95% CI = 0.98-1.27; death: HR = 1.16, 95% CI = 1.05-1.28; cardiovascular death: HR = 1.12, 95% CI = 0.99-1.27). Conclusion High resting heart rate is a risk factor for adverse outcomes in patients with HFpEF, and future studies are needed in order to determine whether reducing heart rate improves outcomes in HFpEF.

Entities:  

Keywords:  Heart failure; heart rate; preserved ejection fraction

Mesh:

Substances:

Year:  2017        PMID: 28482692      PMCID: PMC5577984          DOI: 10.1177/2047487317708676

Source DB:  PubMed          Journal:  Eur J Prev Cardiol        ISSN: 2047-4873            Impact factor:   7.804


  15 in total

1.  Differential impact of heart rate and blood pressure on outcome in patients with heart failure with reduced versus preserved left ventricular ejection fraction.

Authors:  Micha T Maeder; David M Kaye
Journal:  Int J Cardiol       Date:  2010-10-28       Impact factor: 4.164

2.  2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America.

Authors:  Clyde W Yancy; Mariell Jessup; Biykem Bozkurt; Javed Butler; Donald E Casey; Monica M Colvin; Mark H Drazner; Gerasimos Filippatos; Gregg C Fonarow; Michael M Givertz; Steven M Hollenberg; JoAnn Lindenfeld; Frederick A Masoudi; Patrick E McBride; Pamela N Peterson; Lynne Warner Stevenson; Cheryl Westlake
Journal:  J Am Coll Cardiol       Date:  2016-05-20       Impact factor: 24.094

3.  Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial.

Authors:  Marc A Pfeffer; Brian Claggett; Susan F Assmann; Robin Boineau; Inder S Anand; Nadine Clausell; Akshay S Desai; Rafael Diaz; Jerome L Fleg; Ivan Gordeev; John F Heitner; Eldrin F Lewis; Eileen O'Meara; Jean-Lucien Rouleau; Jeffrey L Probstfield; Tamaz Shaburishvili; Sanjiv J Shah; Scott D Solomon; Nancy K Sweitzer; Sonja M McKinlay; Bertram Pitt
Journal:  Circulation       Date:  2014-11-18       Impact factor: 29.690

4.  Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction.

Authors:  Akshay S Desai; Eldrin F Lewis; Rebecca Li; Scott D Solomon; Susan F Assmann; Robin Boineau; Nadine Clausell; Rafael Diaz; Jerome L Fleg; Ivan Gordeev; Sonja McKinlay; Eileen O'Meara; Tamaz Shaburishvili; Bertram Pitt; Marc A Pfeffer
Journal:  Am Heart J       Date:  2011-11-08       Impact factor: 4.749

5.  The relationship between resting heart rate and peak VO2: A comparison of atrial fibrillation and sinus rhythm.

Authors:  Yuko Kato; Shinya Suzuki; Tokuhisa Uejima; Hiroaki Semba; Osamu Nagayama; Etsuko Hayama; Takeshi Yamashita
Journal:  Eur J Prev Cardiol       Date:  2016-02-15       Impact factor: 7.804

6.  Spironolactone for heart failure with preserved ejection fraction.

Authors:  Bertram Pitt; Marc A Pfeffer; Susan F Assmann; Robin Boineau; Inder S Anand; Brian Claggett; Nadine Clausell; Akshay S Desai; Rafael Diaz; Jerome L Fleg; Ivan Gordeev; Brian Harty; John F Heitner; Christopher T Kenwood; Eldrin F Lewis; Eileen O'Meara; Jeffrey L Probstfield; Tamaz Shaburishvili; Sanjiv J Shah; Scott D Solomon; Nancy K Sweitzer; Song Yang; Sonja M McKinlay
Journal:  N Engl J Med       Date:  2014-04-10       Impact factor: 91.245

7.  Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study.

Authors:  Karl Swedberg; Michel Komajda; Michael Böhm; Jeffrey S Borer; Ian Ford; Ariane Dubost-Brama; Guy Lerebours; Luigi Tavazzi
Journal:  Lancet       Date:  2010-09-11       Impact factor: 79.321

8.  Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial.

Authors:  Sanjiv J Shah; John F Heitner; Nancy K Sweitzer; Inder S Anand; Hae-Young Kim; Brian Harty; Robin Boineau; Nadine Clausell; Akshay S Desai; Rafael Diaz; Jerome L Fleg; Ivan Gordeev; Eldrin F Lewis; Valetin Markov; Eileen O'Meara; Bondo Kobulia; Tamaz Shaburishvili; Scott D Solomon; Bertram Pitt; Marc A Pfeffer; Rebecca Li
Journal:  Circ Heart Fail       Date:  2012-12-20       Impact factor: 8.790

9.  Impact of elevated heart rate on clinical outcomes in patients with heart failure with reduced and preserved ejection fraction: a report from the CHART-2 Study.

Authors:  Tsuyoshi Takada; Yasuhiko Sakata; Satoshi Miyata; Jun Takahashi; Kotaro Nochioka; Masanobu Miura; Soichiro Tadaki; Hiroaki Shimokawa
Journal:  Eur J Heart Fail       Date:  2013-12-31       Impact factor: 15.534

Review 10.  Adrenergic nervous system in heart failure: pathophysiology and therapy.

Authors:  Anastasios Lymperopoulos; Giuseppe Rengo; Walter J Koch
Journal:  Circ Res       Date:  2013-08-30       Impact factor: 17.367

View more
  6 in total

Review 1.  Devices and interventions for the prevention of adverse outcomes of tachycardia on heart failure.

Authors:  Jasneet Devgun; Yash B Jobanputra; Michael Arustamyan; Robert Chait; Waqas Ghumman
Journal:  Heart Fail Rev       Date:  2018-07       Impact factor: 4.214

Review 2.  Heart failure with preserved ejection fraction: current management and future strategies : Expert opinion on the behalf of the Nucleus of the "Heart Failure Working Group" of the German Society of Cardiology (DKG).

Authors:  Carsten Tschöpe; Christoph Birner; Michael Böhm; Oliver Bruder; Stefan Frantz; Andreas Luchner; Lars Maier; Stefan Störk; Behrouz Kherad; Ulrich Laufs
Journal:  Clin Res Cardiol       Date:  2017-10-10       Impact factor: 5.460

Review 3.  How Heart Rate Should Be Controlled in Patients with Atherosclerosis and Heart Failure.

Authors:  Rose Mary Ferreira Lisboa da Silva; Anaisa Silva Roever Borges; Nilson Penha Silva; Elmiro Santos Resende; Gary Tse; Tong Liu; Leonardo Roever; Giuseppe Biondi-Zoccai
Journal:  Curr Atheroscler Rep       Date:  2018-09-17       Impact factor: 5.113

4.  Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.

Authors:  Nicole Martin; Karthick Manoharan; Ceri Davies; R Thomas Lumbers
Journal:  Cochrane Database Syst Rev       Date:  2021-05-22

Review 5.  Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.

Authors:  Nicole Martin; Karthick Manoharan; James Thomas; Ceri Davies; R Thomas Lumbers
Journal:  Cochrane Database Syst Rev       Date:  2018-06-28

6.  ECG-AI: electrocardiographic artificial intelligence model for prediction of heart failure.

Authors:  Oguz Akbilgic; Liam Butler; Ibrahim Karabayir; Patricia P Chang; Dalane W Kitzman; Alvaro Alonso; Lin Y Chen; Elsayed Z Soliman
Journal:  Eur Heart J Digit Health       Date:  2021-10-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.